These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

656 related items for PubMed ID: 26949218

  • 1. Soluble prion protein and its N-terminal fragment prevent impairment of synaptic plasticity by Aβ oligomers: Implications for novel therapeutic strategy in Alzheimer's disease.
    Scott-McKean JJ, Surewicz K, Choi JK, Ruffin VA, Salameh AI, Nieznanski K, Costa ACS, Surewicz WK.
    Neurobiol Dis; 2016 Jul; 91():124-131. PubMed ID: 26949218
    [Abstract] [Full Text] [Related]

  • 2. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers.
    Laurén J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM.
    Nature; 2009 Feb 26; 457(7233):1128-32. PubMed ID: 19242475
    [Abstract] [Full Text] [Related]

  • 3. MRZ-99030 - A novel modulator of Aβ aggregation: II - Reversal of Aβ oligomer-induced deficits in long-term potentiation (LTP) and cognitive performance in rats and mice.
    Rammes G, Gravius A, Ruitenberg M, Wegener N, Chambon C, Sroka-Saidi K, Jeggo R, Staniaszek L, Spanswick D, O'Hare E, Palmer P, Kim EM, Bywalez W, Egger V, Parsons CG.
    Neuropharmacology; 2015 May 26; 92():170-82. PubMed ID: 25637092
    [Abstract] [Full Text] [Related]

  • 4. Therapeutic significance of NR2B-containing NMDA receptors and mGluR5 metabotropic glutamate receptors in mediating the synaptotoxic effects of β-amyloid oligomers on long-term potentiation (LTP) in murine hippocampal slices.
    Rammes G, Hasenjäger A, Sroka-Saidi K, Deussing JM, Parsons CG.
    Neuropharmacology; 2011 May 26; 60(6):982-90. PubMed ID: 21310164
    [Abstract] [Full Text] [Related]

  • 5. Soluble Prion Protein Binds Isolated Low Molecular Weight Amyloid-β Oligomers Causing Cytotoxicity Inhibition.
    Williams TL, Choi JK, Surewicz K, Surewicz WK.
    ACS Chem Neurosci; 2015 Dec 16; 6(12):1972-80. PubMed ID: 26466138
    [Abstract] [Full Text] [Related]

  • 6. Alzheimer's therapeutics targeting amyloid beta 1-42 oligomers I: Abeta 42 oligomer binding to specific neuronal receptors is displaced by drug candidates that improve cognitive deficits.
    Izzo NJ, Staniszewski A, To L, Fa M, Teich AF, Saeed F, Wostein H, Walko T, Vaswani A, Wardius M, Syed Z, Ravenscroft J, Mozzoni K, Silky C, Rehak C, Yurko R, Finn P, Look G, Rishton G, Safferstein H, Miller M, Johanson C, Stopa E, Windisch M, Hutter-Paier B, Shamloo M, Arancio O, LeVine H, Catalano SM.
    PLoS One; 2014 Dec 16; 9(11):e111898. PubMed ID: 25390368
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Dextran sulfate sodium inhibits amyloid-β oligomer binding to cellular prion protein.
    Aimi T, Suzuki K, Hoshino T, Mizushima T.
    J Neurochem; 2015 Aug 16; 134(4):611-7. PubMed ID: 25963375
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The flavonoid baicalein rescues synaptic plasticity and memory deficits in a mouse model of Alzheimer's disease.
    Gu XH, Xu LJ, Liu ZQ, Wei B, Yang YJ, Xu GG, Yin XP, Wang W.
    Behav Brain Res; 2016 Sep 15; 311():309-321. PubMed ID: 27233830
    [Abstract] [Full Text] [Related]

  • 14. Alzheimer's therapeutics targeting amyloid beta 1-42 oligomers II: Sigma-2/PGRMC1 receptors mediate Abeta 42 oligomer binding and synaptotoxicity.
    Izzo NJ, Xu J, Zeng C, Kirk MJ, Mozzoni K, Silky C, Rehak C, Yurko R, Look G, Rishton G, Safferstein H, Cruchaga C, Goate A, Cahill MA, Arancio O, Mach RH, Craven R, Head E, LeVine H, Spires-Jones TL, Catalano SM.
    PLoS One; 2014 Sep 15; 9(11):e111899. PubMed ID: 25390692
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The Small Molecule GAL-201 Efficiently Detoxifies Soluble Amyloid β Oligomers: New Approach towards Oral Disease-Modifying Treatment of Alzheimer's Disease.
    Russ H, Mazzanti M, Parsons C, Riemann K, Gebauer A, Rammes G.
    Int J Mol Sci; 2022 May 21; 23(10):. PubMed ID: 35628602
    [Abstract] [Full Text] [Related]

  • 19. Identification of prion protein-derived peptides of potential use in Alzheimer's disease therapy.
    Nieznanska H, Bandyszewska M, Surewicz K, Zajkowski T, Surewicz WK, Nieznanski K.
    Biochim Biophys Acta Mol Basis Dis; 2018 Jun 21; 1864(6 Pt A):2143-2153. PubMed ID: 29604335
    [Abstract] [Full Text] [Related]

  • 20. The anti-prion RNA aptamer R12 disrupts the Alzheimer's disease-related complex between prion and amyloid β.
    Iida M, Mashima T, Yamaoki Y, So M, Nagata T, Katahira M.
    FEBS J; 2019 Jun 21; 286(12):2355-2365. PubMed ID: 30916478
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.